Core Insights - Shuttle Pharmaceuticals is advancing its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, having successfully dosed the first three patients [1][2] - The company has finalized agreements with six clinical trial sites, including major cancer centers, to conduct the trial [1][2] - Shuttle Pharma has improved its financial position by paying off a 4.5 million public offering [1][2] Company Developments - The Phase 2 clinical trial will enroll 40 patients with IDH wild-type, methylation negative glioblastoma, aiming to determine the optimal dose of Ropidoxuridine [3] - The trial is expected to take 18 to 24 months to complete, with the primary endpoint being survival compared to historical controls [3] - The company aims to leverage radiation sensitizers to enhance cancer treatment outcomes and improve patient quality of life [6] Market Opportunity - Approximately 800,000 patients in the US receive radiation therapy for cancer annually, with 400,000 treated for curative purposes [4] - The market for radiation sensitizers is projected to grow by over 22% in the next five years, indicating significant potential for Shuttle Pharma's products [4]
Shuttle Pharma Provides Third Quarter 2024 Corporate Update